Methods for modulating inflammatory and/or immune responses

• US 8,221,741 B2
• Filed: 01/11/2008
• Issued: 07/17/2012
• Est. Priority Date: 01/17/2007
• Status: Active Grant

• Current Assignee: Stemnion, Inc.
• Original Assignee: Stemnion, Inc.
• Inventors: Marshall, Vivienne S., Banas, Richard A., Trumpower, Catherine J.
• Primary Examiner(s): Marvich, Maria
• Application Number:
  US12/448,903
• Publication Number:
  US 20100068180A1
• Time in Patent Office: 1,649 Days
• Field of Search: None
• US Class Current: 424/93.21
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: C12N 2501/23 Interleukins [IL]
• CPC Class Codes: C12N 2502/02 embryonic cells
• CPC Class Codes: C12N 5/0605 Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
• CPC Class Codes: C12N 5/0636 T lymphocytes

Abstract

The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.

Claims

1. A method for down-regulating the immune response a subject'"'"'s peripheral blood mononuclear cells (PBMCs) exhibit when they are exposed to an antigen present on a transplanted tissue, the method comprising the step of contacting the subject PBMCs with a purified population of CD117-negative Amnion-derived Multipotent Progenitor (AMP) cells prior to exposure of the subject to the transplanted tissue, such that the AMP cells down-regulate the immune response exhibited by the PBMCs upon exposure to the transplanted tissue.

2. The method of claim 1 wherein the immune response is an autoimmune response.

3. The method of claim 1 wherein the immune response is an allogeneic response.

4. The method of claim 1 wherein the PBMCs are further contacted with one or more active agents.

5. The method of claim 4 wherein the one or more active agents is selected from the group consisting of a corticosteroid, a cyclosporine, a tacrolimus, a sirolimus, a methotrexate, an azathiopine, a mercatopurine, a cytotoxic antibiotic, a polyclonal antibody, a monoclonal antibody, an interferon, an opioid, a TNF binding protein, a mycophenolate, a FTY720, and another cell type.

6. The method of claim 5 wherein the monoclonal antibody is selected from the group consisting of an anti-T-cell receptor (CD23) and an anti-IL2 receptor (CD25) antibody.